Opening

Le capcommundes actionnaires.

An editorial and community platform for shareholders who want to understand, engage with, and dialogue constructively with the companies they own.

Read the manifesto See the companies we cover

Recent activity

Nov 3, 2026Oculis · Q3 2026 results: cash of $252.0M (CHF 210.3M) at 30 September, runway into 2H 2029 reiterated; quarterly net loss of CHF 18.2M (vs CHF 16.9M); PREDICT-1 topline still expected around year-end 2026 and privosegtor IND clearance in acute MS relapses in Q4 2026; R&D Day on 8 Dec. at the St. Regis New York; LifeSci and Sofinnova Growth and Innovation Summit (16 Nov., London), Piper Sandler (1–3 Dec., New York) and J.P. Morgan Healthcare (11–14 Jan. 2027, San Francisco) conferences
Nov 3, 2026Medincell · UZEDY® US net sales of $85M in Q3 2026 (+96% YoY) per Teva's results, for $225M over nine months, above the $191M of full-year 2025; Teva raises its 2026 outlook again to $290–310M (from $270–290M); Medincell earns mid-to-high single-digit royalties and remains eligible for up to $105M in commercial milestone payments
Nov 2, 2026Oculis · Prof. Björn Tackenberg, M.D., Ph.D. (formerly Roche, Head of Integrative Neuroscience & Medical Practice) appointed Chief Scientific Officer, with initial priorities on privosegtor in the PIONEER program, acute MS relapses and other neurological indications; Aaron Tansy, M.D., joins as VP, Development Franchise Head, Neurology; participation listed at the Guggenheim Healthcare Innovation (9–11 Nov.) and Stifel Healthcare (10–12 Nov.) conferences
Oct 29, 2026Oculis · privosegtor featured at the 6th APOIS Congress (Seoul, 30 Oct.–1 Nov. 2026; CEO Riad Sherif presenting the PIONEER program on 1 Nov.) and at the CNS Summit (Everett, MA, 1–4 Nov. 2026; Phase 2 ACUITY results presented on 2 and 3 Nov.); the company reiterates it expects IND clearance in acute MS relapses in Q4 2026
Oct 22, 2026Oculis · new biomarker data from the Phase 2 ACUITY trial presented at ACTRIMS-ECTRIMS (MSToronto 2026): with privosegtor, smaller rise in plasma NfL and GFAP levels than with placebo after acute optic neuritis, particularly at early timepoints; the company considers the data consistent with the previously reported low-contrast visual acuity gains and retinal preservation
Oct 20, 2026Oculis · new plasma biomarker analyses (NfL, GFAP) from the Phase 2 ACUITY trial of privosegtor in optic neuritis to be presented in a late-breaking session at the 10th Joint ACTRIMS-ECTRIMS Meeting (Toronto, 21–23 Oct 2026; presentation on 22 Oct); R&D Day set for 8 December 2026

II.

On screen

Video

On CapCordia

CapCordia Shareholders' Pact·June 2026

III.

Posture

« We are not an activist fund. We are not trying to impose a vision. We offer common ground — that of an informed shareholder base that understands, questions, and engages. Without aggression, without complacency. »

Read the manifesto

IV.

Approach

Our approach

Three pillars, one standard: quality.

Sourced editorial

Structured company files: thesis, catalysts, risks, calendar. Facts, not noise.

Constructive dialogue

A posture of mutual engagement with management. CapCordia is common ground, not combative activism.

Qualified community

Long-term shareholders who share a rigorous reading of the files and prepare for general meetings.

Coverage

Companies covered

Companies we cover

CapCordia is built around a small number of deeply researched files.

Key partnersTeva · AbbVie

FDA-approved productsUZEDY® · WELTRUZA™

French biotech based near Montpellier, specialised in long-acting injectable formulations through its BEPO® platform. FY 2025-26 marks the acceleration of the transition toward a stable royalty model: UZEDY® (Teva, schizophrenia) generated $215M in net sales (+52.5% YoY), and olanzapine LAI (TEV-‘749) was approved by the FDA on 9 October 2026 as WELTRUZA™, the second approved product built on Medincell technology, with a US launch by Teva expected in the following weeks.

Biotechnology · Specialty drug deliveryOpen the file

HeadquartersLausanne · Reykjavík

Swiss/Icelandic ophthalmology biotech listed on Nasdaq (OCS). After the DIAMOND pivotal-trial failure (OCS-01 in diabetic macular oedema, 29 May 2026), Oculis is repositioning around neuro-ophthalmology with two assets in registrational trials: licaminlimab (OCS-02) in severe dry eye disease — PREDICT-1 topline expected around year-end 2026 — and privosegtor (OCS-05), a neuroprotective candidate whose programme is expanding from optic neuritis (PIONEER) to acute multiple sclerosis relapses (positive FDA pre-IND feedback in August 2026). In August 2026, Oculis signed the acquisition from Accure Therapeutics of full worldwide ownership of privosegtor (and the preclinical candidate ACT-02), moving from licensee to owner of its lead asset. Cash of $252.0M (CHF 210.3M) at 30 September 2026, stated runway into 2H 2029.

Biotechnology · OphthalmologyOpen the file